• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GCPII(N-乙酰-α-D-半乳糖胺酶)抑制可预防1型糖尿病BB/Wor大鼠的长期糖尿病神经病变。

GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.

作者信息

Zhang W, Slusher B, Murakawa Y, Wozniak K M, Tsukamoto T, Jackson P F, Sima A A F

机构信息

Department of Pathology, Wayne State University, 540 E. Canfield Ave, Detroit, MI 48201, USA.

出版信息

J Neurol Sci. 2002 Feb 15;194(1):21-8. doi: 10.1016/s0022-510x(01)00670-0.

DOI:10.1016/s0022-510x(01)00670-0
PMID:11809162
Abstract

AIMS/HYPOTHESIS: Hyperglutamatergic activity induced by ischemia is believed to underlie neuronal damage in a variety of neurological disorders, including neuropathic pain. Since ischemia is believed to be a prominent mechanism involved in diabetic polyneuropathy (DPN), we investigated the effect of the glutamate carboxypeptidase II (GCPII, EC #3.4-17.21; previously termed NAALADase), an enzyme responsible for the hydrolysis of the neuropeptide NAAG to NAA and glutamate, on the development of DPN in type 1 diabetic BB/Wor rats.

METHODS

Diabetic animals were treated with 10 mg/kg/day i.p. of the selective GCPII inhibitor GPI-5232 from onset of diabetes for 6 months. Hyperalgesia to thermal stimulation and nerve conduction velocity (NCV) were measured monthly. The effect on structural DPN was assessed by scoring of single, teased myelinated fibers, myelinated fiber morphometry and ultrastructural examination of C-fibers at 6 months.

RESULTS

GCPII inhibition showed significant but partial effects on hyperalgesia (p<0.001), nerve conduction slowing (p<0.01) axonal and nodal structural changes (p<0.001), small myelinated fiber atrophy, and degenerative changes of C-fibers.

CONCLUSIONS

GCPII inhibition has beneficial effects on hyperalgesia, nerve function, and structural degenerative changes in DPN, which are likely mediated by inhibition of ischemia-induced glutamate release.

摘要

目的/假设:缺血诱导的高谷氨酸能活性被认为是包括神经性疼痛在内的多种神经系统疾病中神经元损伤的基础。由于缺血被认为是糖尿病性多发性神经病(DPN)的一个突出机制,我们研究了谷氨酸羧肽酶II(GCPII,EC编号3.4 - 17.21;以前称为N - 乙酰天门冬氨酰 - L - 丙氨酸二肽酶),一种负责将神经肽NAAG水解为NAA和谷氨酸的酶,对1型糖尿病BB/Wor大鼠DPN发展的影响。

方法

糖尿病动物从糖尿病发病开始,每天腹腔注射10 mg/kg的选择性GCPII抑制剂GPI - 5232,持续6个月。每月测量对热刺激的痛觉过敏和神经传导速度(NCV)。6个月时通过对单根、 teased有髓纤维评分、有髓纤维形态计量学和C纤维超微结构检查评估对结构性DPN的影响。

结果

GCPII抑制对痛觉过敏(p<0.001)、神经传导减慢(p<0.01)、轴突和结的结构变化(p<0.001)、小有髓纤维萎缩以及C纤维的退行性变化有显著但部分的影响。

结论

GCPII抑制对DPN的痛觉过敏、神经功能和结构退行性变化有有益作用,这可能是通过抑制缺血诱导的谷氨酸释放介导的。

相似文献

1
GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.GCPII(N-乙酰-α-D-半乳糖胺酶)抑制可预防1型糖尿病BB/Wor大鼠的长期糖尿病神经病变。
J Neurol Sci. 2002 Feb 15;194(1):21-8. doi: 10.1016/s0022-510x(01)00670-0.
2
The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy.GCPII(N-乙酰-α-神经氨酸酶)抑制对疼痛性和感觉性糖尿病神经病变的预防和治疗作用。
J Neurol Sci. 2006 Sep 25;247(2):217-23. doi: 10.1016/j.jns.2006.05.052. Epub 2006 Jun 15.
3
C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats.C肽可改善1型糖尿病BB/Wor大鼠的神经病变。
Diabetes Metab Res Rev. 2007 Jan;23(1):63-70. doi: 10.1002/dmrr.672.
4
Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes.无髓鞘纤维感觉神经病变在1型和2型糖尿病中有所不同。
Diabetes Metab Res Rev. 2005 Sep-Oct;21(5):448-58. doi: 10.1002/dmrr.541.
5
C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat.C肽可预防和改善BB/Wor大鼠的慢性I型糖尿病多发性神经病变。
Diabetologia. 2001 Jul;44(7):889-97. doi: 10.1007/s001250100570.
6
A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats.II型糖尿病BBZDR/Wor大鼠和I型糖尿病BB/Wor大鼠的糖尿病性多发性神经病比较。
Diabetologia. 2000 Jun;43(6):786-93. doi: 10.1007/s001250051376.
7
Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BB/W-rat.阿卡波糖长期抑制餐后高血糖可延缓BB/W大鼠神经病变的发展。
Diabetologia. 1992 Apr;35(4):325-30. doi: 10.1007/BF00401199.
8
C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats.C肽可纠正1型BB/Wor大鼠的神经内膜血流,但不能纠正其氧化应激。
Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E497-505. doi: 10.1152/ajpendo.00048.2004. Epub 2004 May 4.
9
Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy.在1型糖尿病性神经病变中,是胰岛素缺乏而非高血糖导致神经营养反应受损和神经纤维再生障碍。
J Neuropathol Exp Neurol. 2003 Mar;62(3):260-71. doi: 10.1093/jnen/62.3.260.
10
Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.半乳糖血症会产生与糖尿病性神经病变类似的、ARI可预防的节点变化。
Diabetes Res Clin Pract. 1994 Sep;25(2):117-29. doi: 10.1016/0168-8227(94)90037-x.

引用本文的文献

1
Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function.抑制脑谷氨酸羧肽酶II(GCPII)以增强认知功能。
Adv Pharmacol. 2025;102:27-63. doi: 10.1016/bs.apha.2024.10.018. Epub 2024 Nov 5.
2
Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects.药物化学中的膦酸盐和膦酸盐前药:过去的成功与未来的前景
Front Chem. 2022 May 20;10:889737. doi: 10.3389/fchem.2022.889737. eCollection 2022.
3
Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
(5-甲基-2-氧代-1,3-二氧杂环戊烯-4-基)甲基(ODOL)基前药提高 2-(膦酸甲基)戊二酸(2-PMPA)的口服生物利用度。
Mol Pharm. 2019 Oct 7;16(10):4292-4301. doi: 10.1021/acs.molpharmaceut.9b00637. Epub 2019 Sep 24.
4
Role of mitochondria in diabetic peripheral neuropathy: Influencing the NAD-dependent SIRT1-PGC-1α-TFAM pathway.线粒体在糖尿病周围神经病变中的作用:影响 NAD 依赖性 SIRT1-PGC-1α-TFAM 通路。
Int Rev Neurobiol. 2019;145:177-209. doi: 10.1016/bs.irn.2019.04.002. Epub 2019 Jun 8.
5
Sequence-Dependent Interfacial Adsorption and Permeation of Dipeptides across Phospholipid Membranes.二肽跨磷脂膜的序列依赖性界面吸附和渗透。
J Phys Chem B. 2017 Oct 26;121(42):9859-9867. doi: 10.1021/acs.jpcb.7b08238. Epub 2017 Oct 16.
6
Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.经鼻腔给予其γ-取代酯前药后,2-(膦酰甲基)戊二酸的脑内传递增强。
Mol Pharm. 2017 Oct 2;14(10):3248-3257. doi: 10.1021/acs.molpharmaceut.7b00231. Epub 2017 Aug 31.
7
Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.鼻内给药后GCP-II抑制剂2-PMPA的中枢神经系统选择性摄取。
PLoS One. 2015 Jul 7;10(7):e0131861. doi: 10.1371/journal.pone.0131861. eCollection 2015.
8
Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.用于前列腺特异性膜抗原的基于底物的成像剂的合成与生物学评价
Macromol Res. 2013 May 1;21(5):565-573. doi: 10.1007/s13233-013-1050-5.
9
Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats.谷氨酸羧肽酶II抑制在行为和生理上改善了大鼠中吡哆醇诱导的神经病变。
PLoS One. 2014 Sep 25;9(9):e102936. doi: 10.1371/journal.pone.0102936. eCollection 2014.
10
Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.谷氨酸羧肽酶 II 抑制剂 E2072 的二硫键可还原,导致体内系统暴露时间延长。
Drug Metab Dispos. 2012 Dec;40(12):2315-23. doi: 10.1124/dmd.112.046821. Epub 2012 Sep 4.